Stem Cell Therapy Project
Daniel, John, Magno, Thahn, Victor, Vivian show the world just exactly what stem cells really are.
By: John Peterman
Read the original:
Stem Cell Therapy Project - Video
Stem Cell Therapy - BioLogic Anti-Aging Skin Cream
http://www.ReadTheReviewsFirst.com Truvisage Anti-Aging Skin Care International Is Better Than Botox!
By: Greg Smith
Read more from the original source:
Stem Cell Therapy - BioLogic Anti-Aging Skin Cream - Video
Cell Therapy Limited on Crowdcube - Repairing Broken Hearts
HeartcelTM is a novel stem cell therapy that can regenerate the heart following heart failure - a Cell Therapy Ltd Medicine.
By: Cell Therapy Ltd
See the original post here:
Cell Therapy Limited on Crowdcube - Repairing Broken Hearts - Video
Stem Cell Therapy to Treat Equine Tendon Injuries
A brief explanation of tendon injuries and how stem cell therapy can be used to treat them.
By: Animal Science
More here:
Stem Cell Therapy to Treat Equine Tendon Injuries - Video
Stem cells transformed into heart tissue
In a breakthrough process, scientists are transforming stem cells into actual beating heart tissue. It could someday lead to new drug treatments for heart disease or even lab-created hearts...
By: CBSNews.com Web Extras
Read more here:
Stem cells transformed into heart tissue - Video
Stem Cells Repair All Body Organs
World #39;s First - Stem Cell Enhancer.
By: Dave W Easter
Go here to see the original:
Stem Cells Repair All Body Organs - Video
Genetically engineered stem cells to make and secrete toxins that kill brain cancer cells
Genetically engineered stem cells to make and secrete toxins that kill brain cancer cells. Subscribe this channel to watch more motivational, inspirational, valuable and informative videos...
By: Health Mind Body Spirit
Read more:
Genetically engineered stem cells to make and secrete toxins that kill brain cancer cells - Video
Global Cell Expansion Market Research Report 2019
New Market Research Report on Cell Expansion Market by Product (Reagent, Media, Serum, Bioreactors, Centrifuge), Cell Type (human, animal), Application (Stem Cell Research, Regenerative...
By: David clark
See the original post:
Global Cell Expansion Market Research Report 2019 - Video
Stem Cell Therapy Anti Aging Skin Cream Review and Exclusive Deal
http://www.ReadTheReviewsFirst.com Truvisage Anti-Aging Skin Care System Free Trial.
By: Greg Smith
Excerpt from:
Stem Cell Therapy Anti Aging Skin Cream Review and Exclusive Deal - Video
Leah Still prepares for stem-cell procedure
CINCINNATI (Perry Schaible) -- Devon Still has shared his story with the world. He uses social media to keep well-wishers up to date on Leah #39;s progress. The most recent post was Leah at...
By: LOCAL 12
View post:
Leah Still prepares for stem-cell procedure - Video
November 25, 2014
Provided by Peter Bracke, UCLA
Understanding the self-replication mechanisms is critical for improving stem cell therapies for blood-related diseases and cancers
Led by Dr. Hanna Mikkola, a member of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, UCLA scientists have discovered a protein that is integral to the self-replication of hematopoietic stem cells during human development.
The discovery lays the groundwork for researchers to generate hematopoietic stem cells in the lab that better mirror those that develop in their natural environment. This could in turn lead to improved therapies for blood-related diseases and cancers by enabling the creation of patient-specific blood stem cells for transplantation.
The findings are reported online ahead of print in the journal Cell Stem Cell.
Researchers have long been stymied in their efforts to make cell-based therapies for blood and immune diseases more broadly available, because of an inability to generate and expand human hematopoietic stem cells (HSCs) in lab cultures. They have sought to harness the promise of pluripotent stem cells (PSCs), which can transform into almost any cell in the human body, to overcome this roadblock. HSCs are the blood-forming cells that serve as the critical link between PSCs and fully differentiated cells of the blood system. The ability of HSCs to self-renew (replicate themselves) and differentiate to all blood cell types, is determined in part by the environment that the stem cell came from, called the niche.
In the five-year study, Mikkola, Dr. Sacha Prashad and Dr. Vincenzo Calvanese, members of Mikkolas lab and lead authors of the study, investigated a HSC surface protein called GPI-80. They found that it was produced by a specific subpopulation of human fetal hematopoietic cells that were the only group that could self-renew and differentiate into various blood cell types. They also found that this subpopulation of hematopoietic cells was the sole population able to permanently integrate into and thrive within the blood system of a recipient mouse.
Mikkola and colleagues further discovered that GPI-80 identifies HSCs during multiple phases of human HSC development and migration. These include the early first trimester of fetal development when newly generated human hematopoietic stem cells can be found in the placenta, and the second trimester when HSCs are actively replicating in the fetal liver and the fetal bone marrow.
We found that whatever HSC niche we investigated, we could use GPI-80 as the best determinant to find the stem cell as it was being generated or colonized different hematopoietic tissues, said Mikkola, associate professor of molecular, cell and development biology at UCLA and also a member of the Jonsson Comprehensive Cancer Center. Moreover, loss of GPI-80 caused the stem cells to differentiate into mature blood cells rather than HSCs. This essentially tells us that GPI-80 must be present to make HSCs. We now have a very unique marker for investigating how human hematopoietic cells develop, migrate and function.
Go here to read the rest:
UCLA Researchers Identify Protein Key To The Development Of Blood Stem Cells
Episode 7.2 Stem Cells Inc THE STEM CELL REVIEW
Martin McGlynn, President and CEO of Stem Cell Inc. after the story behind Stem Cell Inc, presents his company approach using stem cells for neuroprotection....
By: Jean-Loup Romet-Lemonne
The rest is here:
Episode 7.2 Stem Cells Inc THE STEM CELL REVIEW - Video
MEDIPOST America
Antonio Lee, Ph.D., CEO Managing Director Private Company Headquarters: Maryland, U.S. MEDIPOST is a leading stem cell biotechnology company focused on dev...
By: Alliance for Regenerative Medicine
Read more from the original source:
MEDIPOST America - Video
Stem Cell Therapy at EmCell clinic: Dr. Khalil Fadel story
By:
More:
Stem Cell Therapy at EmCell clinic: Dr. Khalil Fadel story - Video
Cambridge stem cell pioneer DefiniGEN is in China this week showcasing technology that arguably gives the UK a world lead in countering liver and pancreatic cancer.
The young company is seeking Chinese partners to broaden the reach of the technology which holds a potentially significant payback in regenerative medicine.
With US global stem cell innovator Roger Pedersen among its technology founders, DefiniGEN was founded two years ago to commercialise a stem cell production platform developed at the University of Cambridge.
The platform generates human liver and pancreatic cell types using Nobel Prize winning human Induced Pluripotent Stem Cell (iPSC) technology.
DefiniGEN is visiting Shanghai and Beijing on a trade mission organised by UKTI East of England in partnership with the China-Britain Business Council.
The company is actively looking to partner with Life Science distributors and pharmaceutical drug discovery companies in China. CEO Dr Marcus Yeo and Dr Masashi Matsunaga business development manager for Asia Pacific - are spearheading the initiative.
The visit includes a range of medically-focused ventures from one to one meetings with key players to presentations at UK consulates.
DefiniGEN cells are provided to the drug discovery sector for use in lead optimisation and toxicity programmes.
The companys OptiDIFF platform produces validated libraries of disease-modelled human liver cells for a range of diseases. The phenotype (the composite of an organisms traits) and pathology of the diseases is pre-confirmed in the cells.
The technology provides pharmaceutical companies with more predictive in vitro cell products enabling the development of safer and more effective treatments.
View original post here:
Cambridge stem cell pioneer targets China partners
Freeport, Grand Bahama (PRWEB) November 25, 2014
Okyanos, the leader in cell therapy, announced the adoption of body-jet eco for use in the harvesting of adult stem cells for use in cell therapy. The Okyanos procedure begins with the extraction of a small amount of body fat, a process done using advanced water-jet assisted liposuction technology. The body-jet eco system is utilized during this procedure and allows a larger number of viable adult stem cells to be harvested. After separating the cells from fat tissue, the Okyanos medical doctor immediately injects these cells into and around the area needing treatment allowing targeting of the cells to repair damaged tissue.
According to Dr. Todd Malan, Chief Cell Therapy Officer and General Surgeon at Okyanos, who was involved in helping develop the appropriate settings of the body-jet eco use in adult stem cell harvesting, The body-jet eco was used during our first stem cell procedure at Okyanos. It performed flawlessly as expected and we feel it meets our tough standards. This is much gentler and more precise, making the overall procedure faster with less trauma to the surrounding tissue and less diversion of the adult stem cells from the intended area.
The body-jet eco is part of the water-jet assisted liposuction (WAL) family of devices, which detaches the fat gently from the tissue structure using a flat, fan-shaped water jet spray. The surrounding connective tissue, nerves and blood vessels remain in-tact which makes this procedure much gentler on the patient and leads to a quicker recovery with less pain medication required. The WAL process has a very high viability of fat cells and stem cells with a high take rate after fat grafting. The WAL family of devices is manufactured by human med AG with its headquarters in Schwerin, Germany, and distributed in North America by CAREstream America with its headquarters in Altamonte Springs, Florida.
Because the treatment is minimally invasive it requires that patients be under only moderate sedation. Post-procedural recovery consists of rest in a private suite for several hours that comfortably accommodates up to 3 family members.
Patients can contact Okyanos at http://www.okyanos.com or by calling toll free at 1-855-659-2667.
About CAREstream America: CAREstream America began in 2013 and is a division of CAREstream Medical Ltd, which has serviced Canadian customers respiratory and anesthesia needs for over 15 years. CAREstream America retains North American distribution rights to the full water-jet assisted human med AG product line. CAREstream America is the premier distributor of Aesthetic product lines ranging from water-jet assisted technology to vascular access imaging to nitrous oxide analgesia which help shape the body, showcase the veins and relieve the pain and anxiety of aesthetic procedures.
About Dr. Malan: Todd Malan, MD, serves as the Chief Cell Therapy Officer and General Surgeon at Okyanos Heart Institute, overseeing the liposuction and stem cell isolation step of the Okyanos cardiac cell therapy process. Known as an innovative cosmetic surgeon, Dr. Malans practices combine the most progressive and minimally-traumatic liposuction technologies available. A pioneer of fat-derived stem cell therapies, he became the first physician in the US to utilize stem cells from fat for soft tissue reconstruction in October, 2009, combining water-assisted liposuction, fat transfer and adult stem cell technologies.
About Okyanos: (Oh key AH nos) Based in Freeport, Grand Bahama, Okyanos brings a new standard of care and a better quality of life to patients with coronary artery disease, tissue ischemia, autoimmune diseases, and other chronic neurological and orthopedic conditions. Okyanos Cell Therapy utilizes a unique blend of stem and regenerative cells derived from patients own adipose (fat) tissue which helps improve blood flow, moderate destructive immune response and prevent further cell death. Okyanos is fully licensed under the Bahamas Stem Cell Therapy and Research Act and adheres to U.S. surgical center standards. The literary name Okyanos, the Greek god of the river Okyanos, symbolizes restoration of blood flow.
Read more:
Okyanos Adopts WAL/ body-jet eco for Use in Cell Therapy
Chuck Bednar for redOrbit.com Your Universe Online
A new stem cell gene therapy developed by researchers at UCLA is set to begin clinical trials early next year after the technique reportedly cured 18 children who were born without working immune systems due to a condition known as ADA-deficient Severe Combined Immunodeficiency (SCID) or Bubble Baby disease.
The treatment was developed by Dr. Donald Kohn, a member of the UCLA Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, and his colleagues, and according to the university, it is able to identify and correct faulty genes by using the DNA of the youngsters born with this life-threatening condition.
Left untreated, ADA-deficient SCID is often fatal within the first year of a childs life, reports Peter M. Bracke for UCLA. However, after more than three decades of research, Dr. Kohns team managed to develop a gene therapy that can safely restore the immune systems of children with the disease by using their own cells and with no noticeable side effects.
All of the children with SCID that I have treated in these stem cell clinical trials would have died in a year or less without this gene therapy, instead they are all thriving with fully functioning immune systems, Dr. Kohn, who is also a professor of pediatrics and of microbiology, immunology and molecular genetics, said in a recent statement.
Children born with SCID have to be isolated in a controlled environment for their own safety, because without an immune system, they are extremely vulnerable to illnesses and infections that could be deadly. While there are other treatments for ADA-deficient SCID, Dr. Kohn noted that they are not always optimal or feasible for many children. The new technique, however, provides them with a cure, and the chance to live a full healthy life.
SCID is an inherited immunodeficiency that is typically diagnosed about six months after birth, the researchers said, and children with the condition are so vulnerable to infectious diseases that even the common cold could prove fatal to them. This particular form of the condition causes cells to not create ADA, an enzyme essential for the production of the white blood cells which are a vital component of a healthy, normally-functioning immune system.
Approximately 15 percent of all SCID patients are ADA-deficient, according to the university, and these youngsters are typically treated by being injected twice per week with the required enzyme. This is a process that must continue throughout a patients entire life, and even then it doesnt always work to bring their immune systems to optimal levels. Alternately, they could undergo bone marrow transplants from matched siblings, but those matches are rare and the transplanted cells themselves are often rejected by the childs body.
Dr. Kohn and his colleagues tested two therapy regimens on 18 ADA-deficient SCID over the course of two multi-year clinical trials starting in 2009. During the trials, the blood stem cells of the patients were removed from their bone marrow and genetically modified in order to correct the defect. All 18 of the patients were cured.
The technique used a virus delivery system first developed in Dr. Kohns laboratory in the 1990s a technique which inserts the corrected gene that produces the ADA into the blood forming stem cells in the bone marrow. The genetically corrected blood-forming stem cells will then produce the T-cells required to combat infections.
Link:
New Stem Cell Treatment Found To Cure 'Bubble Baby' Disease
UCLA Stem Cell Researchers Announce Gene Therapy Cure for 18 Bubble Baby Patients
Researchers at UCLA announced today that they had cured 18 children who were born with the so-called Bubble Baby disease, a genetic disorder that leaves the young sufferers without a working...
By: UCLA Eli Edythe Broad Center of Regenerative Medicine and Stem Cell Research
See the original post:
UCLA Stem Cell Researchers Announce Gene Therapy Cure for 18 Bubble Baby Patients - Video
The website you are visiting is owned and operated by Infomercial.TV, Inc. We understand your concerns regarding collection of your personal data. We appreciate your trust and respect your privacy.
Except as otherwise disclosed in this Privacy Policy, we do not sell or disclose information that identifies you personally or makes it possible for other parties to contact them directly without your consent.
Security: We use the Secure Sockets Layer (SSL), an advanced security protocol that protects your credit card information and ensures secure online ordering. SSL Internet connections are encrypted, and thus protect all credit card ordering information, including your name, address and credit card number, so it cannot be read in transit. We use secure technology, privacy protection controls, and restrictions on employee access, to safeguard your personal information.
Collection of Information: We only collect personally identifiable information about you via this website when you provide it in connection with a request for a product, service, or information. For example, if you decide to place an order, we will ask you for your shipping and billing address, phone number, email address, credit card number and its expiration date. When you enter your personally identifiable information on this website, you are giving your consent to the collection, use and disclosure of your personal information as set forth in this Privacy Policy. If you would prefer that we not collect any personally identifiable information from you, please do not provide us with any such information.
We may also collect, store or accumulate certain non-personally identifiable information concerning your use of this website, such as information regarding which of our pages are most popular.
This website is intended for adults. We do not knowingly collect personal information from children under the age of 13. However, if the parent or guardian of a child under 13 believes that the child has provided us with personally identifiable information, the parent or guardian of that child should contact us at info@infomercial.tv if they want this information deleted from our files so that it is not in retrievable form. If we otherwise obtain knowledge that we have personally identifiable information about a child under 13 in retrievable form in our files, we will delete that information from our existing files so that it is not retrievable.
Use of Cookies: We also use cookies to assign identification to your computer. The unique user ID contained within your cookie automatically identifies your computer to our servers every time you visit our website. Cookies by themselves cannot be used to find out the identity of any user, but may be correlated with identity information in our log files. You can turn off the cookie feature by using your browser preference options.
Use of Pixel Tags: We also collect information through the use of pixel tags included in email messages we may send to you. Pixel tags are tiny graphic files, not visible to the human eye, that are included in HTML-encoded email messages. When such a message is opened in an HTML-capable email program, the recipient's computer will access our server to retrieve the pixel tag file, allowing us to record and store, along with the recipient's email address, the date and time the recipient viewed the email message, the fact that the recipient's email program is capable of receiving HTML-encoded email, and other standard logging information. The pixel tag also may see or read cookies.
Third Parties: We may rely on other companies and individuals to perform functions on our behalf. Examples include data analysis firms, customer support specialists, web hosting companies, and fulfillment companies (e.g., companies that fill product orders or coordinate mailings). We may share personally identifiable information with such third parties as appropriate for them to perform their functions. We may also share personally identifiable information with marketing partners or other direct marketers, so they can send you notices about products or services that may be of interest to you. If you do not want to receive marketing communications from them, see the Opt-Out section below.
Our website may offer links to and from other third party sites. These third parties have separate data collection and privacy practices independent from ours, and thus we cannot be responsible for their policies or activities. Please contact those third parties directly if you have questions about their privacy policies.
Read more:
genucel - Intensive New Stem Cell Eye Therapy Treatment ...
Human Ken doll: Rodrigo Alves, who spent 125,000 on surgery, now has stem cell hair treatment
Real life Ken doll Rodrigo Alves spent 125000 on surgery to turn himself into a human Ken doll has become the first person in the UK to have stem cell hair treatment Rodrigo Alves, 30, has...
By: AmazingWorldNews
View original post here:
Human Ken doll: Rodrigo Alves, who spent 125,000 on surgery, now has stem cell hair treatment - Video